Tests exercise and atorvastatin alongside cancer treatment in several cancers
Tests guided exercise and atorvastatin with cancer drugs in adults with several cancers.
Plain-language title generated from the registry record
Registry title: Measuring Oncological Value of Exercise and Statin
Key facts
- Where
- Tampere, FinlandSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT05796973, who can take part
Where in Finland
- Tampere University HospitalTampere, FinlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tampere University Hospital
- Trial code
- NCT05796973
- Record updated
- 27 June 2025
- Original description
The aim of the study is to find out whether supervised physical exercise during cancer drug treatment improves the effectiveness of the treatment in metastasized breast, kidney, ovarian and prostate cancer compared to unsupervised exercise. In addition, the investigators are investigating whether the use of atorvastatin combined with guided group exercise training would further improve the response to cancer treatment.Read full original descriptionShow less
Syöpäpotilaan Ennusteen Parantaminen Muuttamalla syövän mikroympäristöä ja Metaboliaa Liikunnalla ja lääkkeellisesti - Measuring Oncological Value of Exercise and Statin
The aim of the study is to find out whether supervised physical exercise during cancer drug treatment improves the effectiveness of the treatment in metastasized breast, kidney, ovarian and prostate cancer compared to unsupervised exercise. In addition, the investigators are investigating whether the use of atorvastatin combined with guided group exercise training would further improve the response to cancer treatment.
Inclusion: The patient has metastatic prostate cancer, breast cancer, ovarian cancer or kidney cancer confirmed histologically and by imaging, for which 1st-line cancer drug treatment is started; Prostate cancer: First course of docetaxel treatment or second-generation antiandrogen treatment for metastatic prostate cancer; Breast cancer: First-line medical treatment of metastatic breast cancer regardless of hormone receptor status; Kidney cancer: Kidney cancer, for which 1st-line cancer drug treatment is started as tki monotherapy and/or IO monotherapy or as a combination therapy; Ovarian cancer: stage III or IV cancer for which chemotherapy treatment is started; The patient agrees to the study and signs a written informed consent; Adult (18 years=>) women (breast, ovarian and kidney cancer) and men (prostate and kidney cancer) are recruited for the study; In women, the use of a reliable contraceptive during the intervention.
Exclusion: Active use of cholesterol-lowering drugs; Troublesome side effects that occurred in the past during cholesterol medication; Inability to physical exertion and/or unsuitability for cancer drug treatment; Severe liver or kidney failure; Inability to physical exertion and/or unsuitability for cancer drug treatment; Severe liver or kidney failure; High risk of bone fractures; Poor co-operation ability for psychological reasons; Continuous use of medicinal substances that interact with atorvastatin during the study period; A special group of subjects according to the EU Clinical Trials Regulation 536/2014 (e.g. pregnant or lactating women); High risk of bone fractures; Poor co-operation ability for psychological reasons; A special group of subjects according to the EU Clinical Trials Regulation 536/2014 (e.g. pregnant or lactating women).